Regorafenib
Approved · EMAAlso known as Stivarga, Régorafénib, REGORAFENIB ANHYDROUS, Regorafenibum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Targeted therapy for hepatocellular carcinoma.
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered… Show full indicationShow less
Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib; hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2
- ESMO open1
- Journal of experimental & clinical cancer research : CR1
- Lancet (London, England)1
- Signal transduction and targeted therapy1
- Adelberg D1
- Agulnik M1
- Akashi K1
- Ananda S1
- Attia S1
- Baba E1
- Baumhauer A1
- Bodoky G1
- Taipei Veterans General Hospital2
- 1 Knight Cancer Institute1
- 10 Indiana University1
- 11 Mayo Clinic Rochester1
- 13 Duke Cancer Institute1
- 14 Mayo Clinic Jacksonville1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Regorafenib in the shared literature.
Studied across 5 of the same disease areas as Regorafenib in the shared literature.
Studied across 3 of the same disease areas as Regorafenib in the shared literature.
Studied across 4 of the same disease areas as Regorafenib in the shared literature.
Studied across 3 of the same disease areas as Regorafenib in the shared literature.
Studied across 2 of the same disease areas as Regorafenib in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.